629 related articles for article (PubMed ID: 22356288)
1. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
2. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
3. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
[TBL] [Abstract][Full Text] [Related]
5. Rationale for cholesteryl ester transfer protein inhibition.
Hewing B; Fisher EA
Curr Opin Lipidol; 2012 Aug; 23(4):372-6. PubMed ID: 22517614
[TBL] [Abstract][Full Text] [Related]
6. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
7. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
Nurmohamed NS; Ditmarsch M; Kastelein JJP
Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Filippatos TD; Klouras E; Barkas F; Elisaf M
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
[TBL] [Abstract][Full Text] [Related]
10. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
Doggrell SA
Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
[TBL] [Abstract][Full Text] [Related]
11. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
Armitage J; Holmes MV; Preiss D
J Am Coll Cardiol; 2019 Feb; 73(4):477-487. PubMed ID: 30704580
[TBL] [Abstract][Full Text] [Related]
12. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Barter P; Rye KA
Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
[TBL] [Abstract][Full Text] [Related]
13. Structure-based mechanism and inhibition of cholesteryl ester transfer protein.
Xue H; Zhang M; Liu J; Wang J; Ren G
Curr Atheroscler Rep; 2023 Apr; 25(4):155-166. PubMed ID: 36881278
[TBL] [Abstract][Full Text] [Related]
14. New horizons for cholesterol ester transfer protein inhibitors.
Schwartz GG
Curr Atheroscler Rep; 2012 Feb; 14(1):41-8. PubMed ID: 22083134
[TBL] [Abstract][Full Text] [Related]
15. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
Murín J; Pernický M; Kiňová S
Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
[TBL] [Abstract][Full Text] [Related]
17. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
Miyares MA; Davis K
Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
[TBL] [Abstract][Full Text] [Related]
18. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
Ghosh RK; Ghosh SM
Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840
[TBL] [Abstract][Full Text] [Related]
19. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
